UOC
GPCR icon

UBS O'Connor’s Structure Therapeutics GPCR Stock Holding History

UBS O'Connor’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,520
Closed -$529K – 389
2024
Q4 		$529K Buy
19,520
+1,520
+8% +$53.9K 0.01% 278
2024
Q3 		$790K Buy
+18,000
New +$696K 0.02% 302
2023
Q4 		– Sell
-12,218
Closed -$616K – 549
2023
Q3 		$616K Buy
12,218
+2,025
+20% +$65.3K 0.01% 381
2023
Q2 		$424K Sell
10,193
-11,857
-54% -$332K 0.01% 457
2023
Q1 		$525K Buy
+22,050
New +$518K 0.01% 462

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

UBS O'Connor's GPCR Position: Q1 2025 in Review

UBS O'Connor sold out of Structure Therapeutics (GPCR) in Q1 2025, closing a stake of 19,520 shares — an estimated $529K sold.

UBS O'Connor first reported a position in GPCR in Q1 2023 and held it in 5 quarters. The position peaked at $790K in Q3 2024. 150 funds tracked by Wall St. Rank hold GPCR as of Q1 2025.

  • UBS O'Connor reported no remaining Structure Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 19,520 Structure Therapeutics shares in Q1 2025, an estimated $529K.
  • UBS O'Connor first reported a position in Structure Therapeutics in Q1 2023 and held it in 5 quarters.
  • UBS O'Connor's Structure Therapeutics position peaked at $790K in Q3 2024.
  • 150 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.